Universal Cells
Thao Pham is a Scientist II at Universal Cells with experience in single-cell RNA sequencing of human rhabdomyosarcoma spheroid cells and RNA sequencing of chemo-resistant human RMS cancer cell lines. Previously, Thao Pham worked as a Postdoctoral Researcher at the University of Washington - School of Medicine, where they focused on CRISPR/Cas9 gene editing of human RMS cancer cell lines. Thao Pham also has experience as a Research Technician and Graduate Student at various institutions, with a PhD in Pathology from the University of Washington - School of Medicine.
Universal Cells
Universal Cells is a Seattle-based biotech developing, licensing and commercializing stem cell therapies that overcome immune rejection and can be used to create true off-the-shelf therapeutic products. Using the company's proprietary genome editing approach, the company engineers stem cells to prevent expression of polymorphic human leukocyteantigen (HLA) molecules, removing the cause of donor tissue rejection and creating Universal Donor Stem Cells that are compatible with every patient.